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ABSTRACT 
Background. An elevated pre-operative white cell count (WCC) has been associated 
with a worse outcome following coronary artery bypass grafting (CABG). Leukocyte 
sub-types, and in particular the N/L ratio, may, however, convey superior prognostic 
information. We hypothesized that the N/L ratio would predict the outcome of patients 
undergoing surgical revascularization. The current study tests this hypothesis. 
Methods. Baseline clinical details were obtained prospectively in 1,938 patients 
undergoing CABG. The differential leukocyte was measured 1 day before surgery and 
patients were followed-up 3.6 years later. The primary end-point was all-cause mortality. 
Results. The pre-operative N/L ratio was a powerful univariable predictor of mortality 
(hazard ratio [HR] 1.13 per unit, p<0.001). In a backward conditional model, including 
all other study variables, it remained a strong predictor (HR 1.09 per unit, p=0.004). In a 
further model, including the European system for cardiac operative risk evaluation, the 
N/L ratio remained an independent predictor (HR 1.08 per unit, p=0.008). Likewise, it 
was an independent predictor of cardiovascular mortality and predicted death in the 
subgroup of patients with a normal WCC (<10 x 109 per litre). This excess hazard was 
concentrated in patients with a N/L ratio in the upper quartile (>3.36). 
Conclusion. An elevated N/L ratio is associated with a poorer survival after CABG. This 
prognostic utility is independent of other recognized risk factors. 
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Coronary artery bypass grafting (CABG) is associated with a small but significant 
incidence of morbidity and mortality. While methods of risk assessment, such as the 
European system for cardiac operative risk evaluation (EuroSCORE), are widely 
employed, there are limits to their predictive ability.1 There remains, therefore, a need for 
additional methods of risk stratification, particularly if these are easily obtained and 
widely available. 
 
The role of low-grade inflammation in the pathogenesis of atherosclerosis and its acute 
complications is well-recognized,2 and several biological markers of inflammation 
predict cardiovascular risk.3,4 One of the most readily available indices is the total 
leukocyte count. This foretells cardiovascular events in unselected adults,5,6 in patients 
with stable angina,7,8 and in the acute coronary syndromes.9,10 The total white cell count 
(WCC) has also been recently found to predict mortality following CABG.11-13 This may 
reflect an association with the severity and/or activity of atherosclerosis. It may also be 
due to direct cardiac and vascular injury initiated by leukocytes following myocardial 
ischemia. 
 
The total leukocyte count does, however, have limitations – the link between leukocytosis 
and outcome is complex and non-linear,14,15 not all studies reveal an independent 
association16 and many have demonstrated confounding relationships with other risk 
factors such as smoking.17 There is, therefore, interest in analysis of white cell subtypes. 
For example, much of the predictive power of the total leukocyte count is contained in 
the neutrophil component.18-20 Likewise, a reduced lymphocyte count has also been 
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associated with poorer prognosis.15,21,22 The predictive value of these indices has been 
combined by calculating the neutrophil/lymphocyte (N/L) ratio. This may be a more 
powerful predictor of cardiovascular risk than the total WCC or individual white cell 
subtypes.23,24,25 However, the prognostic utility of the N/L ratio has not previously been 
evaluated in patients undergoing surgical revascularization. We hypothesized that, 
particularly given the relationship between leukocytes and the myocardial and vascular 
injury that follows ischemia, the N/L ratio would predict outcome in this setting.  
 
METHODS 
The study complies with the Declaration of Helsinki and ethical approval was granted by 
the local Research Ethics Committee. Between April 2000 and March 2004, 2,076 
consecutive patients underwent CABG in our institution. Seventy-six patients who 
underwent emergency surgery and/or CABG within 1 week of acute myocardial 
infarction were excluded, as were 62 patients who had no pre-operative (<1 week before 
CABG) leukocyte count available. The study cohort comprised the remaining 1,938 
subjects. Baseline clinical data, including Canadian Cardiovascular Society angina status, 
New York Heart Association functional class and the EuroSCORE, were collected 
prospectively. 
 
Two hundred and eight patients (10.7%) underwent other major operative procedures in 
addition to CABG. These included 191 valve replacement or repair procedures (145 
aortic [1 with aortic root replacement], 43 mitral and 3 combined aortic and mitral). 
There were 9 left ventricular aneurysm resections, 3 thoracic aortic procedures (without 
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valve replacement), 2 atrial myxoma resections, 2 ventricular septal defect repairs and 1 
pericardiectomy. 
 
All analyses used the blood sample obtained immediately prior to surgery. Differential 
leukocyte count was obtained using an Advia 2120 Hematology System (Bayer 
HealthCare, Tarrytown, NY). This automated analyser exhibits an excellent correlation 
with manual cell counts and has co-efficients of variation of <2.5% for the total white cell 
count, <1.5% for the neutrophil count and <2.9% for the lymphocyte count.26 The total 
WCC, neutrophil, lymphocyte and monocyte counts were recorded. In addition, the pre-
operative N/L ratio was calculated. 
 
Follow up 
Patients were followed up using a vital events search by the General Register Office for 
Scotland. The primary end-point was all-cause mortality. Cause of death was defined as 
cardiac if this was listed as the primary cause or a contributory factor on the death 
certificate. The duration of hospitalization was also recorded. 
 
Statistical analyses 
Categorical data are summarized using absolute values (percentage). Normally 
distributed continuous data are presented as mean (standard deviation) or, where skewed, 
as median (interquartile range). Survival was described using the Kaplan-Meier method 
and comparison made using the log-rank statistic. Estimations of risk were performed 
using Cox regression. Backward conditional multivariable models of survival were 
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developed. One of these included all variables and a second included white cell indices 
plus the EuroSCORE. Retention in these models was set at a significance level of <0.05. 
 
The hazard associated with different quartiles of N/L ratio was assessed using Cox 
regression, using either the lowest quartile as the reference or comparing the upper 
quartile with all others. Power calculations for the log-rank test were used as an 
approximate method to assess whether the Cox regression would have sufficient power to 
detect differences in hazard between the quartiles. In a comparison of two groups of 483 
patients (the minimum number in each quartile) a hazard ratio of 2 could be detected with 
95% power with a minimum of 100 events (deaths) in the two groups combined. 
 
Comparisons of the clinical characteristics and the duration of post-operative hospital 
stay of patients with differing quartiles of N/L ratio were compared using the chi-squared 
test for trend (for categorical variables) and analysis of variance or the Jonckheere-
Terpstra test (for normally and non-normally distributed continuous variables 
respectively). SPSS version 13.0 (SPSS Inc., Chicago, Illinois) was used for all analyses. 
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RESULTS 
Patient population and outcome 
The study cohort were predominantly male with a median age of 66 years (table I). The 
differential leukocyte count was measured a median of 1 (1-3) day before surgery. The 
median total WCC was 7.5 (6.4-8.9) x 109 per litre with a median N/L ratio of 2.43 (1.86-
3.36). Two-hundred and twenty six patients (12%) had a WCC above 10 x 109 per litre. 
Vital status data were available for all patients. During a median of 3.6 (1.4-4.7) years 
follow-up 177 patients (9%) died, 154 from primarily or partly cardiovascular causes. 
Fifty deaths (28%) occurred within the first 30-days of surgery. 
 
Univariable predictors of mortality 
The total WCC was not predictive of mortality (table I). This remained the case even 
when the total WCC was divided in to categories (<6, 6.0-7.9, 8.0-9.9, 10.0-11.9 and >12 
x 109 per litre) or quartiles (HR 1.01, p=0.86 and HR 0.79 for upper quartile v lowest 
quartile, p=0.29, respectively). A higher neutrophil count was associated with an 
increased risk of death, whereas a lower pre-operative lymphocyte count was a strong 
univariable predictor of mortality: as was the pre-operative N/L ratio (table I). 
 
Multivariable predictors of mortality 
The neutrophil and lymphocyte counts and the N/L ratio are mathematically related. The 
N/L ratio was a stronger univariable predictor of outcome (χ2 27.4) than the neutrophil 
count (χ2 3.2) or lymphocyte count (χ2 18.4) and, in this cohort, when the N/L ratio was 
used its components provided no additional prognostic information. Therefore, the N/L 
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ratio was entered in all subsequent regression models. Likewise, cardiopulmonary bypass 
and cross-clamp times are closely related. The former was, however, the stronger 
predictor of outcome and, when this was available, cross-clamp time provided no 
incremental information regarding prognosis. Cardiopulmonary bypass time was, 
therefore, used in all multivariable models.  
 
The first model included all variables shown in table I except EuroSCORE - which is a 
composite that includes several of these parameters and is widely used to predict peri-
operative risk, but has also been demonstrated to be a useful predictor of long-term 
outcome.27-29 The independent predictors of mortality in this model are shown in table II. 
In a further model, including the pre-operative total WCC, the pre-operative monocyte 
count, the pre-operative N/L ratio and EuroSCORE, the only independent predictors of 
outcome were the N/L ratio (HR 1.08 per unit, 95% CI 1.02-1.15, p=0.008) and the 




When only cardiovascular death was considered an end-point, the N/L ratio remained a 
univariable predictor (HR 1.12 per unit, 95% CI 1.06-1.18, p<0.001), as did the pre-
operative lymphocyte (HR 0.57 per 1x109 per litre, 95% CI 0.44-0.75, p<0.001) and 
monocyte (HR 1.59 per 1x109 per litre, 95% CI 1.16-2.17, p=0.004) counts. In contrast, 
neither the total WCC (HR 0.97 per 1x109 per litre, 95% CI 0.91-1.04, p=0.44) or 
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neutrophil count (HR 1.03 per 1x109 per litre, 95% CI 0.94-1.13, p=0.49) predicted 
cardiovascular mortality. 
 
In a multivariable model, including all variables shown in table I except EuroSCORE the 
N/L ratio remained an independent predictor of cardiovascular death (HR 1.11 per unit, 
95% CI 1.03-1.19, p=0.01), as did the pre-operative monocyte count (HR 1.49 per 1x109 
per litre, 95% CI 1.08-2.05, p=0.02). The other independent predictors of cardiac death 
were time on cardiopulmonary bypass (HR 1.04 per 10 minutes, p<0.001), estimated 
glomerular filtration rate (HR 0.97 per mL/min per 1.73m2, p<0.001), requirement for a 
major cardiac surgical procedure in addition to CABG (HR 1.99, p=0.003), ejection 
fraction <50% (HR 1.91, p=0.001) and diabetes mellitus (HR 1.65, P=0.02). In a model 
including the pre-operative total WCC, the pre-operative monocyte count, the pre-
operative N/L ratio and EuroSCORE, the only independent predictors of cardiovascular 
death were the N/L ratio (HR 1.08 per unit, 95% CI 1.00-1.16, p=0.046) and the 
EuroSCORE (HR 1.28 per unit, 95% CI 1.21-1.35, p<0.001). 
 
Patients with normal white cell count only 
In patients with a normal total WCC (≤10 x 109 per litre, n=1,712) the N/L ratio remained 
a powerful univariable predictor of all-cause mortality (HR 1.18 per unit, 95% CI 1.11-
1.26, p<0.001). The pre-operative lymphocyte count also remained a strong predictor 
(HR 0.51 per 1x109 per litre, 95% CI 0.38-0.68, P<0.001), but neither the total WCC or 
any other leukocyte subsets were predictive of death in this subgroup.  
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In multivariable models, similar to those described above, N/L ratio remained an 
independent predictor of outcome (HR 1.15 per unit, 95% CI 1.07-1.24, p<0.001 in a 
model including all other variables and HR 1.14 per unit, 95% CI 1.06-1.23, p=0.001 in a 
model including total WCC, monocyte count and EuroSCORE). 
 
Quartiles of neutrophil/lymphocyte ratio 
The excess risk was observed in patients with N/L ratios in the upper quartile (table III 
and figure 1). In univariable analysis, the hazard associated with a N/L ratio in the highest 
quartile (v all others) was 2.09, 95% CI 1.54-2.84, p<0.001. In backward conditional 
multivariable models, firstly including all variables shown in table II and then the 
EuroSCORE, pre-operative WCC and monocyte count, the independent hazard associated 
with a N/L ratio in the upper quartile was 1.72, 95% CI 1.25-2.36, p=0.001 and 1.53, 
95% CI 1.13-2.13, p=0.008, respectively. A relationship between the quartile of N/L ratio 
and length of post-operative hospitalization was also observed (p<0.001). Patients with 
higher N/L ratios tended to be older, have poorer renal function and a higher EuroSCORE 
(table IV). They were also more likely to require re-intubation following surgery and had 
a tendency towards higher cardiac troponin I levels at 24 hours following surgery. 
 
DISCUSSION 
The current data demonstrate that in patients undergoing CABG the N/L ratio conveys 
powerful prognostic information that is independent of other conventional clinical risk 
factors. Patients with N/L ratios in the upper quartile are at particularly high risk. 
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Total white cell count 
Prior data have suggested that an elevated leukocyte count is associated with a worse 
cardiovascular outcome in a variety of settings.17 It has also been reported to predict 
increased mortality following CABG.11-13 A relationship between pre-operative total 
WCC and mortality was not observed in the current cohort. The explanation for this is not 
clear. Our cohort is an unselected consecutive population similar to others in which the 
total leukocyte count has proved to be prognostic. Likewise, the mean, median and 
distribution of the WCC are almost identical to those reported in comparable studies.11-13 
Two of these12,13 included emergency and peri-infarct cases. However, Bagger and 
colleagues demonstrated a persisting relationship of WCC in sub-group analysis, when 
emergency and post-infarct cases were excluded.11
 
There is evidence of a biphasic, or J-shaped, relationship between total WCC and 
mortality following myocardial infarction30 and percutaneous coronary intervention.31 
This might diminish the overall predictive value of the WCC. However, in the current 
cohort we found no evidence of such a relationship - possibly reflecting the selected 
population that undergoes CABG. 
 
The absence of any relationship between total WCC and survival may relate to the effects 
of medication. The Long-term Intervention with Pravastatin in Ischemic Disease study 
showed that the WCC predicted cardiovascular mortality over 6 years in patients 
randomized to placebo, but not in those receiving pravastatin.32 We do not have accurate 
details of statin use in the current population, but in a similar cohort of patients 
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undergoing all forms of cardiac surgery in our institution, post operative statin use was 
78%,33 rising to 87% in patients undergoing CABG (unpublished data). 
 
Leukocyte subtypes 
Despite the absence of an association between total WCC and outcome in this cohort, we 
found lymphocyte and monocyte counts to be significant univariable predictors, with the 
neutrophil count demonstrating a trend towards significance. The improved survival 
associated with a higher lymphocyte count was particularly striking. This has previously 
been observed in patients with stable coronary artery disease,22 those undergoing 'high-
risk' angioplasty14 and those with heart failure.21,34
 
More recently, it has been demonstrated that increased prognostic information could 
obtained by deriving the N/L ratio. In a cohort of 3,227 patients undergoing coronary 
angiography, the N/L ratio was a powerful predictor of mortality - and was independent 
and superior to individual leukocyte subtypes.23 After adjustment for other factors, 
patients with a N/L ratio in the upper quartile had a 3 times higher hazard of death during 
follow-up than those in the lowest quartile.23 Likewise, in 1,046 patients undergoing 
percutaneous coronary intervention, the pre-procedural N/L ratio, but not the total WCC, 
was an independent predictor of all-cause death.24 This was, however, a selected 
population, from which <25% of eligible patients had a differential leukocyte available - 





Both an elevated neutrophil count and a depressed lymphocyte count are associated with 
a worse outcome. It seems likely that the ability to integrate these two facets of the 
differential WCC underpins the particular prognostic utility of the N/L ratio. A higher 
ratio was associated with several major determinants of cardiovascular outcome. 
However, the observed increased hazard is independent of such factors. Analysis of the 
survival curves demonstrates that the excess mortality is concentrated in patients with the 
highest ratio. The curves separate immediately and continue to diverge – suggesting an 
increased risk both in the early post-operative period and in the longer term. 
 
Multiple properties of leukocytes may contribute to peri-operative myocardial damage 
and, thus, a worse outcome. Neutrophil infiltration is associated with secondary damage 
following myocardial ischemia and is implicated in reperfusion injury - through both 
direct toxic effects on the myocardium and vascular endothelium, and leukocyte plugging 
in the microvasculature15,17 In support of this, the use of a neutrophil and platelet depleted 
reperfusate has been associated with a reduction in post-operative myocardial damage.35 
Increased neutrophil counts are also associated with increased blood viscosity and 
hypercoagulability.17 Likewise, cardiopulmonary bypass itself is associated with 
neutrophil activation,36 which may accentuate the effects of elevated pre-operative levels. 
 
The longer-term excess risk associated with an elevated N/L ratio may, in part, reflect the 
consequences of increased peri-operative myocardial injury. Certainly, peri-operative 
myocardial damage is associated with long-term adverse outcome.33 It is likely that it also 
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due to other mechanisms. Atherosclerosis is an inflammatory process,2 and elevation of 
the N/L ratio may reflect a chronic background inflammatory state. Although neutrophils 
play a limited role in atherogenesis they have a major role in the disruption of 
atherosclerotic plaques – and, thereby, influence their progression and the risk of acute 
complications.15,17,19,23,37 Meanwhile, although lymphocytes are also involved in the 
development and progression of atherosclerosis,2 peripheral lymphopenia predicts a 
poorer outcome in patients with stable coronary heart disease.22 The reasons for this are 
not fully understood. The most widely accepted explanation, however, is that a reduced 
lymphocyte count reflects a physiological stress.15,22 Thus, lymphopenia may serve as a 
surrogate marker for the general health of an individual rather than reflecting a protective 
role of lymphocytes per se. It appears, therefore, that the N/L ratio integrates several 
parameters that will determine both the early and later outcome from CABG. 
 
Study strengths and limitations 
This study comprised a large cohort of consecutive patients undergoing non-urgent 
CABG in a regional cardiothoracic centre. The results are, therefore, representative of 
stable patients undergoing surgical revascularization. The use of all-cause mortality as a 
primary end-point provides an objective measure of outcome. However, no data were 
obtained regarding other important morbidities such as peri-operative myocardial 
infarction or stroke. Data are also lacking regarding pre and post-operative medication, 
which may have influenced the outcome of patients, and possibly the N/L ratio itself. 
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The use of a single blood sample does not allow assessment of the stability of the N/L 
ratio in an individual over time and there is some diurnal variation in the differential 
leukocyte count, depending on glucocorticoid levels. Finally, some patients with minor 
sepsis may have been included in the study. Patients were, however, undergoing elective 
surgery that would be re-scheduled if acute infection were suspected clinically. Likewise, 
subgroup analysis of only patients with a normal WCC demonstrates similar results. 
 
Despite these limitations the current data demonstrate a clear relationship between pre-
operative N/L ratio and survival after CABG, with patients in the highest quartile at 
greatest risk. Importantly, this prognostic utility is independent of other well-recognized 
individual risk factors and the EuroSCORE. The N/L ratio, which is easily calculated and 
readily available, may, therefore, assist the risk-stratification of patients undergoing 
surgical revascularization. It remains unclear whether elevation of the N/L ratio directly 
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Age, years 65 ±9 65 ±9 69 ±9 1.06 (1.04-1.08) ∗ <0.001
Risk factors and medical history      
     Male 1,499 (77%) 1,366 (78%) 133 (75%) 0.85 (0.61-1.20) 0.36 
     Current smoker 197 (10%) 180 (10%) 17 (10%) 0.95 (0.58-1.57) 0.86 
     Diabetes 297 (15%) 261 (15%) 36 (20%) 1.54 (1.07-2.22) 0.02 
     Hypertension 1,170 (60%) 1,064 (60%) 105 (59%) 1.07 (0.79-1.44) 0.67 
     Prior PCI 161 (8%) 149 (8%) 12 (7%) 0.86 (0.48-1.55) 0.62 
     Prior CABG 41 (2%) 35 (2%) 6 (3%) 1.56 (0.69-3.53) 0.28 
     Previous MI 953 (49%) 859 (49%) 94 (53%) 1.12 (0.83-1.50) 0.46 
     Estimated LVEF <50%† 662 (34%) 575 (33%) 87 (49%) 1.87 (1.40-2.52) <0.001
CCS angina status‡      
     0 to II 872 (45%) 794 (45%) 78 (45%)   
     III or IV 1,060 (55%) 963 (55%) 97 (55%) 0.88 (0.65-1.19) 0.40 
NYHA functional class#      
     I or II 841 (47%) 774 (47% 67 (41%)   
     III or IV 966 (53%) 868 (53%) 98 (59%) 1.07 (0.78-1.46) 0.68 
EuroSCORE 4 (2-6) 4 (2-6) 6 (4-8) 1.27 (1.21-1.33) <0.001
Renal function      
     Creatinine (mg/dL) 1.21 ±0.43 1.20 ±0.37 1.38 ±0.79 1.49 (1.29-1.73)§ <0.001
     Estimated GFR (mL/min/1.73m2) 63.9 ±14.4 64.4 ±14.0 58.6 ±17.8 0.97 (0.96-0.98)║ <0.001
Differential leukocyte count      
     Total white cell count (x 109 per litre) 7.5 (6.4-8.9) 7.5 (6.4-8.9) 7.5 (6.2-8.7) 0.99 (0.94-1.05) 0.83 
     Neutrophil count (x 109 per litre) 4.7 (3.7-5.8) 4.7 (3.7-5.8) 4.9 (3.8-6.0) 1.07 (0.99-1.16) 0.07 
     Monocyte count (x 109 per litre) 0.4 (0.3-0.5) 0.4 (0.3-0.5) 0.4 (0.3-0.5) 1.58 (1.15-2.16) 0.005 
     Lymphocyte count (x 109 per litre) 1.9 (1.5-2.4) 1.9 (1.5-2.4) 1.6 (1.3-2.2) 0.59 (0.46-0.75) <0.001
     Neutrophil/lymphocyte ratio 2.43 (1.86-3.36) 2.39 (1.84-3.27) 2.79 (2.00-4.22) 1.13 (1.08-1.18) <0.001
Peri-operative data      
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     Pre-operative intra-aortic balloon 74 (4%) 67 (4%) 7 (4%) 1.58 (0.74-3.38) 0.24 
     Additional major cardiac procedure∗∗ 208 (11%) 167 (9%) 41 (23%) 1.72 (1.45-2.05) <0.001
     Number of bypass grafts 2.57 ±0.83 2.58 ±0.83 2.46 ±0.89 0.82 (0.68-0.98) 0.03 
     Internal mammary artery used 1298 (67%) 1212 (69%) 86 (49%) 0.48 (0.36-0.65) <0.001
     Off pump procedure 219 (11%) 207 (12%) 12 (7%) 0.73 (0.40-1.31) 0.28 
     Bypass time (minutes) 79 (59-97) 78 (59-96) 87 (67-123) 1.04 (1.03-1.04)†† <0.001
     Cross clamp time (minutes) 43 (32-53) 43 (32-53) 46 (36-74) 1.07 (1.05-1.09)†† <0.001
 
PCI = percutaneous coronary intervention, CABG = coronary artery bypass grafting, MI = myocardial 
infarction, LVEF = left ventricular ejection fraction, CCS = Canadian Cardiovascular Society, NYHA = 
New York Heart Association, GFR = glomerular filtration rate. 
∗ Hazard ratio per year, § Hazard ratio per mg/dL, ║ Hazard ratio per mL/min/1.73m2, †† Hazard ratio per 10 
minutes 
† LVEF was not defined in 13 cases, ‡ CCS status was not accurately recorded in 6 patients, # NYHA 
functional class was not accurately recorded in 131 patients. Percentages refer to patients with data 
available. ∗∗ see text for details. 
To convert creatinine values to micromols per liter multiply by 88.4. 
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Time on bypass (per 10 minutes) 1.04 1.03-1.05 34.8 <0.001 
Age (per year) 1.04 1.02-1.06 16.2 <0.001 
LV ejection fraction <50% 1.76 1.30-2.37 13.7 <0.001 
Creatinine (mg/dL) 1.38 1.15-1.65 12.2 <0.001 
Neutrophil/lymphocyte ratio 1.09 1.03-1.16 8.3 0.004 
Additional major cardiac procedure 1.64 1.12-2.40 6.4 0.004 
 

























All-cause mortality, n (%) 37 (8%) 34 (7%) 33 (7%) 73 (15%) 
  Unadjusted HR (95% CI) 1 0.89 (0.56-1.42) 0.89 (0.56-1.43) 2.06 (1.39-3.06) ∗ 
  HR adjusted for EuroSCORE (95% CI) 1 0.81 (0.51-1.30) 0.77 (0.48-1.23) 1.42 (0.95-2.15)†
     
Cardiovascular mortality, n (%) 30 (6%) 30 (6%) 31 (6%) 63 (13%) 
  Unadjusted HR (95% CI) 1 0.97 (0.59-1.61) 1.03 (0.63-1.71) 2.19 (1.42-3.39) ∗ 
  HR adjusted for EuroSCORE (95% CI) 1 0.88 (0.53-1.47) 0.88 (0.53-1.46) 1.46 (0.93-2.29)‡
     
Post-operative hospital stay (days) 9 (7-11) 9 (7-11) 9 (7-12) 10 (8-13) 
 
CI = confidence interval, HR = hazard ratio 
∗ p<0.001 quartile 4 v quartile 1, † p=0.09 quartile 4 v quartile 1, ‡ p=0.10 quartile 4 v quartile 1. 
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Table IV. Baseline characteristics and early post-operative complications according to neutrophil/lymphocyte ratio (by 
quartile). 
 




















Age (years) 63 ±9  64 ±9  66 ±9  68 ±9 <0.001 
Male 371 (77%) 377 (78%) 362 (75%) 389 (80%) 0.40 
Creatinine (mg/dL) 1.14 ±0.20  1.17 ±0.23  1.23 ±0.48  1.30 ±0.63  
  
<0.001
Estimated GFR (mL/min/1.73m2) 66.9 ±12.6  65.0 ±13.3  62.6 ±15.0  60.9 ±16.0  <0.001
Hypertension 281 (58%) 281 (58%) 308 (64%) 300 (62%) 0.10 
Diabetes mellitus 72 (15%) 64 (13%) 75 (16%) 86 (18%) 0.15 
Smoker 57 (12%) 54 (11%) 50 (10%) 36 (7%) 0.02 
Previous MI 244 (51%) 227 (47%) 219 (45%) 263 (54%) 0.35 
Estimated LVEF <50%∗ 163 (34%) 149 (31%) 159 (33%) 191 (40%) 0.04 
CCS status III or IV† 255 (53%) 270 (56%) 272 (57%) 263 (54%) 0.66 
NYHA class III or IV‡ 230 (51%) 242 (53%) 240 (53%) 254 (56%) 0.16 
EuroSCORE 3 (2-5) 3 (2-5) 4 (2-6) 5 (3-7) <0.001 
Post-operative re-intubation 3 (1%) 6 (1%) 15 (3%) 19 (4%) <0.001 
New post-operative dialysis 1 (<1%) 4 (1%) 2 (<1%) 7 (1%) 0.06 
Post-operative septicemia# 6 (1%) 8 (2%) 4 (1%) 11 (2%) 0.38 
Post-operative chest infection# 44 (9%) 41 (8%) 44 (10%) 61 (13%) 0.08 
Post-operative atrial dysrhythmia# 99 (20%) 83 (17%) 99 (20%) 120 (25%) 0.07 
Cardiac troponin I at 24 h (ng/mL) 4.27 (2.15-8.77) 4.02 (2.18-8.91) 4.28 (2.26-9.19) 5.06 (2.54-11.40) 0.01 
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Data are expressed as mean (standard deviation) if normally distributed, median (interquartile range) if skewed or number (percentage) of patients if categorical. 
∗ LVEF was not defined in 13 patients, † CCS angina status was not accurately recorded in 6 patients, ‡ NYHA functional class was not accurately recorded in 
131 patients. Percentages refer to patients with data available. # clinically apparent. 




 FIGURE LEGEND 
 
Neutrophil/lymphocyte ratio quartile 1  
Neutrophil/lymphocyte ratio quartile 2  
Neutrophil/lymphocyte ratio quartile 3  
Neutrophil/lymphocyte ratio quartile 4  
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Number at risk    Q1     4
 
        Q2     4
 
        Q3     4
 
        Q4     4Log-rank statistic 23.3, p<0.0013210
Duration of follow-up (years)
83        422         287           262 
86        441         291           275 
83        432         279           263 
86        406         264           242 
